26 research outputs found

    Longitudinal data assessment of global stability index in kale leaves

    Get PDF
    ABSTRACT Kale plants are usually sold “in natura” in street markets and malls. Kale leaves can have their appearance compromised by dehydration and discoloration due to increased post-harvest time exposure. We aimed to analyze the Global Stability Index (GSI) in kale accessions by means of repeated measurement analysis and curve grouping as a complementary form of superior sample identification with regard to post-harvest preservation. Thirty kale accessions were evaluated using a randomized block design with four blocks and five plants per plot. Two commercial leaves per plant were collected, and kept on workbenches in the shade at a temperature of 18 ± 1 °C. Subsequently, the degrees of discoloration and dehydration, total chlorophyll content, and accumulated fresh mass loss were evaluated over a 15-day period. From these data, the GSI was calculated for each day of evaluation. In addition, using mixed models, thirteen co-variance structures were tested. For graphical analysis, thirteen linear and non-linear models were assessed followed by curve grouping using multivariate analysis. The GSI was efficient for differentiating accessions, which became an important tool in post-harvest studies. GSI values were not equally correlated, therefore the use of mixed models became an important approach. The unstructured matrix was the best fit to model the dependence of error. The Melow I model was the best fit for studying the GSI. The accessions UFVJM-10, UFLA-1, COM-1, UFVJM-32, COM-3, UFVJM-8, UFVJM-36 and UFVJM-24, belonging to 3 and 5 clusters, are recommended for crop cultivation and as parental material in breeding programs

    Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

    Get PDF
    BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362
    corecore